Martin Grotheer, MD
Family Medicine · Miami, OKNPI 1750352597
Payments from drug & device makers
Across 149 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$379
- AbbVie$208
- Novo Nordisk$192
- Sunovion Pharmaceuticals Inc.$171
- Xeris Pharmaceuticals, Inc.$139
- plus $649 from 15 others
What the payments were for
- Food & beverage$2,933100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $1,200 |
| GSK | 25 | $379 |
| AbbVie(2 entities) | 14 | $208 |
| Novo Nordisk | 14 | $192 |
| Sunovion Pharmaceuticals Inc. | 16 | $171 |
| Xeris Pharmaceuticals, Inc. | 6 | $139 |
| Merck | 7 | $96 |
| Boehringer Ingelheim | 6 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $83 |
| Lundbeck LLC | 3 | $61 |
| Johnson & Johnson | 3 | $50 |
| Eisai Inc. | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Viatris Specialty LLC | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $32 |
| Novartis | 2 | $30 |
| Almatica Pharma LLC | 1 | $18 |
| Corium, LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Metacel Pharmaceuticals LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$334
- BEVESPI AEROSPHERE$332
- FARXIGA$276
How this compares
$2,939 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 279 | $208,111 |
| EliquisApixaban | 297 | $134,676 |
| IngrezzaValbenazine Tosylate | 27 | $108,106 |
| OzempicSemaglutide | 84 | $83,404 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 110 | $71,514 |
| JanuviaSitagliptin Phosphate | 88 | $69,710 |
| FarxigaDapagliflozin Propanediol | 107 | $57,983 |
| PerserisRisperidone | 16 | $48,221 |
| TrintellixVortioxetine Hydrobromide | 77 | $45,063 |
| AristadaAripiprazole Lauroxil | 12 | $38,276 |
| LinzessLinaclotide | 67 | $33,833 |
| TrulicityDulaglutide | 22 | $30,512 |
| RexultiBrexpiprazole | 19 | $24,574 |
| JardianceEmpagliflozin | 34 | $22,564 |
| XareltoRivaroxaban | 30 | $20,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $379 | $227,646335 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $1,200 | $129,498217 claims |
| MerckJanuvia, Janumet | $96 | $85,011104 claims |
| Novo NordiskOzempic | $192 | $83,40484 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat | $87 | $49,86687 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $83 | $45,06377 claims |
| AbbVieLinzess | $208 | $33,83367 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $35 | $24,57419 claims |
| Johnson & JohnsonXarelto | $50 | $20,70430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Miami
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.